[EN] CONJUGATION OF PHARMACEUTICALLY ACTIVE AGENTS WITH TRANSTHYRETIN LIGANDS THROUGH ADJUSTABLE LINKERS TO INCREASE SERUM HALF-LIFE<br/>[FR] CONJUGAISON D'AGENTS PHARMACEUTIQUEMENT ACTIFS AVEC DES LIGANDS DE TRANSTHYRÉTINE PAR DES LIANTS RÉGLABLES POUR AUGMENTER LA DEMI-VIE DE SÉRUM
申请人:ALHAMADSHEH MAMOUN M
公开号:WO2016025129A1
公开(公告)日:2016-02-18
A delivery system for active agents, and methods of making and using the systems, are provided. The delivery systems have (i) a ligand that is selective for an endogeneous plasma protein in the serum of a subject; and, (ii) a linker configured for operatively attaching the ligand covalently to an active agent to increase the half-life of the active agent in the serum.
提供了一种用于活性成分的递送系统,以及制造和使用这些系统的方法。这些递送系统具有:(i) 一种选择性地与受试者血清中的内源性血浆蛋白结合的配体;以及 (ii) 一个连接物,配置为以共价键的方式将配体操作地附着到活性成分上,以增加活性成分在血清中的半衰期。
CONJUGATION OF PHARMACEUTICALLY ACTIVE AGENTS WITH TRANSTHYRETIN LIGANDS THROUGH ADJUSTABLE LINKERS TO INCREASE SERUM HALF-LIFE
申请人:ALHAMADSHEH MAMOUN M.
公开号:US20160045609A1
公开(公告)日:2016-02-18
A delivery system for active agents, and methods of making and using the systems, are provided. The delivery systems have (i) a ligand that is selective for an endogeneous plasma protein in the serum of a subject; and, (ii) a linker configured for operatively attaching the ligand covalently to an active agent to increase the half-life of the active agent in the serum.
Systems for stabilizing and delivering active agents
申请人:Alhamadsheh Mamoun M
公开号:US10172959B2
公开(公告)日:2019-01-08
A delivery system for active agents, and methods of making and using the systems, are provided. The delivery systems have (i) a ligand that is selective for an endogeneous plasma protein in the serum of a subject; and, (ii) a linker configured for operatively attaching the ligand covalently to an active agent to increase the half-life of the active agent in the serum.
The teachings provide active agents that are conjugated with delivery systems that increase the half-life, and reduce the immunogenicity, of the active agents. Methods of making and using the systems are also provided. The delivery systems have (i) a ligand that is selective for an endogeneous plasma protein in the serum of a subject; and, (ii) a linker configured for operatively attaching the ligand covalently to an active agent to increase the half-life of the active agent in the serum.
The teachings provide methods of delivering active agents that are conjugated with delivery systems that increase the half-life, and reduce the immunogenicity, of the active agents. Delivery systems and methods of making and using the delivery systems are also provided. The delivery systems have (i) a ligand that is selective for an endogeneous plasma protein in the serum of a subject; and, (ii) a linker configured for operatively attaching the ligand covalently to an active agent to increase the half-life of the active agent in the serum.